Publikationen (Auswahl)

The Role of Abacavir (ABC, 1592) in Antiretroviral Therapy-Experienced Patients: Preliminary 48-Week Results from a Randomized Double-Blind Trial. Katlama C, Clotet B,  Plettenberg A, Jost J, Arastéh K, Bernasconi E, Jeantils V, Cutrell A, Purdon S, Stone C, Ait-Khaled M; Interscience Conference on Antimicrobial Agents and Chemotherapy. NCBI PubMed AIDS. 2000 May 5;14(7):781-9.

GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine. K Arasteh, R Wood, M Müller, W Prince, L Cass, KH Moore, N Dallow, A Jones, A Klein, V Burt, JP Kleim. HIV clinical trials 2001 Jul-Aug.

Enfurvirtide in combination with an optimized backgraound regimen vs OB alone: week 24 response among categories of baseline demographics, treatmentexperience, and HIV antiretroviral resistance. J Lange, A Lazzarin, B Clotet, D Cooper, J Reynes, K  Arastéh. Int Cong Drug Therapy Hv 2002 Nov 17-21;6:Abstract No. PL14.3.

An Open-Label Assessment of TMC 125 – A New, Next-Generation NNRTI, for 7 Days in HIV-1 Infected Individuals With NNRTI Resistance. Brian G. Gazzard; Anton L. Pozniak; Willy Rosenbaum; G. Patrick Yeni; Schlomo Staszewski; Keikawus Arastéh; Karin De Dier; Monika Peeters; Brian Woodfall; Justin Stebbing; Gerben A. E. vant‘ Klooster. AIDS 17(18):F49-F54, 2003.

Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52. Yeni P, MacGregor T, Gathe J, Arastéh K, Jayaweera D, Jemsek J, Hawkins T, Cameron W, Bodsworth N, McCallister S, Kohlbrenner V, Quinson A, Leith J, Sabo J, Mayers D. Abstr 10th Conf Retrovir Oppor Infect Feb 10 14 2003 Hynes Conv Cent Boston Mass USA Conf Retrovir Oppor Infect 10th 2003 Boston Mass. 2003 Feb 10-14; 10: abstract no. 528.

Enfuvirtide TORO Studies: 48-Week Results Confirm 24-Week Findings. C. Katlama, K. Arastéh, B. Clotet, D.Cooper, K. Henry, J. Lalezari, A. Lazzarin, J. Montaner, M. Nelson, M. O’Hearn, P. Piliero, J. Reynes, B. Trottier, S. Walmsley, R. DeMasi, J. Delehanty, J. Chung, M. Salgo. 2nd IAS Conference on HIV Pathogenesis and Treatment: Paris, France, July 13-16, 2003

The Effects of Enfuvirtide Therapy on Body Composition and Serum Lipids through 48 Weeks in the TORO Trials. Cooper D, Reiss P, Henry K, Nelson M, O’Hearn M, Piliero P, Reynes J, Arastéh K, Chung J, Guimaraes D, Kinchelow T, Bertasso A; the TORO 1 and TORO 2 study groups; Conference on Retroviruses and Opportunistic Infections (11th : 2004 : San Francisco, Calif.). Program Abstr Conf Retrovir Oppor Infect 11th 2004 San Franc Calif. 2004 Feb 8-11; 11: abstract no. 715

TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. Arastéh K, Lazzarin A, Clotet B, Lalezari J, Cooper D, Henry K, O’Hearn M, Reynes J, Piliero P, Trottier B, Montaner J, Walmsley S, Nelson M, Katlama C, Chung J, DeMasi R, Guimaraes D, Huson L, Donatacci L, Wat C, Kinchelow T, Bertasso A, Miralles GD, Salgo M. Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. MoOrB1058.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. N Engl J Med. 2003 May 29;348(22):2186-95.

Sustained Anti-HIV-1 Effect of Racivir Combined with D4T and Sustiva Following a 14-day Treatment of Infected Volunteers. Otto MJ, Arasteh K, Kreckel P, Drauz D, Beard A, Cartee L, Hurwitz SJ, Liotta DC, Schinazi RF, Murphy RL. Abstr 10th Conf Retrovir Oppor Infect 2003 Boston Mass. 2003 Feb 10-14; 10: abstract no. 552.

Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52. Yeni P, MacGregor T, Gathe J, Arastéh K, Jayaweera D, Jemsek J, Hawkins T, Cameron W, Bodsworth N, McCallister S, Kohlbrenner V, Quinson A, Leith J, Sabo J, Mayers D. Abstr 10th Conf Retrovir Oppor Infect Feb 10 14 2003 Boston Mass. 2003 Feb 10-14; 10: abstract no. 528.

Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor Experienced Patients: BI 1182.52. Gathe J, Kohlbrenner VM, Pierone G, Arastéh K, Rubio R, LaLonde R, Piliero P, McCallister S, Garfinkel S, Chaves R, Mukwaya GM, Dohnanyi C, Shaw S, Drees U, Mayers D. Abstr 10th Conf Retrovir Oppor Infect Boston Mass. 2003 Feb 10-14; 10: abstract no. 179.

Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, Schneider L, Kurowski M. Antimicrobial Agents and Chemotherapy, Nov 2004, p. 4148-4153, Vol. 48, No. 11.

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Wood R, Arastéh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ.Antimicrobial Agents and Chemotherapy, Jan 2004, p. 116-23, Vol. 48 No.1.

A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients. Robin Wood, Joseph Eron, Keikawus Arastéh,  Eugenio Teofilo, Christian Trepo, Jean-Michel Livrozet, Jane Yeo, Judith Millard, Mary Beth Wire and Odin J. Naderer. Clinical Infectious Diseases 2004;39:591–594.

Safety, Pharmacokinetics, and Efficacy of (+/–)-ß-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients. C. Herzmann, K. Arastéh, R. L. Murphy, H. Schulbin, P. Kreckel, D. Drauz, R. F. Schinazi, A. Beard, L. Cartee, and M. J. Otto.Antimicrobial Agents and Chemotherapy, Jul 2005, p. 2828-33, Vol. 49, No.7.

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. Arastéh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E; TMC114-C207 Study Team. NCBI PubMed AIDS. 2005 Jun 10;19(9):943-7.

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. Robin Wood, Keikawus Arastéh, Hans-Jürgen Stellbrink, Eugenio Teofilo, François Raffi, Richard B. Pollard, Joseph Eron, Jane Yeo, Judith Millard, Mary Beth Wire and Odin J. Naderer. Antimicrobial Agents and Chemotherapy Jan 2004, p 116-23, Vol. 48 No. 1.

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks. Benoit Trottier, MD; Sharon Walmsley, MD; Jacques Reynes, MD, PhD; Peter Piliero, MD; Mary O’Hearn, MD; Mark Nelson, MA, MBBS, MRCP; Julio Montaner, MD; Adriano Lazzarin, MD; Jacob Lalezari, MD; Christine Katlama, MD; Keith Henry, MD; David Cooper, MD, DSc; Bonaventura Clotet, MD, PhD; Keikawus Arastéh, MD; Jean-François Delfraissy, MD; Hans-Jürgen Stellbrink, MD; Joep Lange, MD, PhD; Daniel Kuritzkes, MD; Joseph J Eron, Jr MD; Calvin Cohen, MD, MSc; Tosca Kinchelow, MD; Anne Bertasso, BS; Emily Labriola-Tompkins, BA; Anna Shikhman, BSN, MBA; Belinda Atkins; Laurence Bourdeau, PhD; Christopher Natale, MSc; Fiona Hughes, BSc; Jain Chung, PhD; Denise Guimaraes, MS; Claude Drobnes, MD; Silvia Bader-Weder, MD; Ralph DeMasi, PhD; Lynn Smiley, MD; Miklos P Salgo, MD, PhD. Journal of Acquired Immune Defic Syndr. 2005;40(4):413-421.

Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arastéh K, López P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D. Clin Infect Dis. 2006 Nov 15;43(10):1347-56.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.  Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group. Lancet. 2007 Jul 7; 370(9581):39-48.

Efficacy and Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-ExperiencedHIV Type 1-Infected Patients. Joseph C. Gathe jr, Gerald Pierone, Peter Piliero, Keikawus Arastéh, Rafael Rubio, Richard G. Lalone, David Cooper, Adriano Lazzarin, Veronika M. Kohlbrenner, Catharine Dohnanyi, John Sabo and Douglas Mayers. AIDS Research and Human Retroviruses Vol. 23, No. 2, 2007, pp. 216–223.

Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration. Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmüller J, Becker M, Arastéh K, Kurowski M. Journal of Antimicrobial Chemotherapy 2007; 59:560-4.

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG. Journal of Acquirerd Immune Defic Syndr. 2008 Apr 1;47(4):429-40.

Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). K. Arastéh, L. Weitner, S. Fenske, B. Kuhlmann, M. Freiwald, R. Ebrahimi, L. Gallo, B. Ranneberg, T. Mertenskoetter. Eur J Med Res (2009) 14:195-199.

Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Keikawus Arastéh, Armin Rieger, Patrick Yeni, Anton Pozniak, Griet Boogaerts, Rolf van Heeswijk, Marie-Pierre P de Béthune, Monika Peeters, and Brian Woodfall. Antiviral Therapy 14(5):713 (2009) PMID 19704175

Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/ emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results. V. Soriano, S. Köppe, H. Mingrone, T. Lutz, M. Opravil, J. Andrade-Villanuev. Lutz, M. Opravil, J. Andrade-Villanueva, F. Antunes, G. Di Perri, D. Podzamczer, S. Taylor, A. Horban, D. Duiculescu, L. de Rossi. Poster, 5th IAS Conference 2009

ASSESSMENT OF THE STEADY STATE PK PARAMETERS OF TWO EXTENDED RELEASE (XR) NEVIRAPINE (NVP) TABLETS 400 MG AND 300 MG QD COMPARED WITH IMMEDIATE RELEASE (IR) NVP TABLETS 200 MG BID IN HIV-1 INFECTED PATIENTS – THE ERVIR STUDY M. Battegay, K. Arasteh, A. Plettenberg, J. Bogner, N. Brockmeyer, O. Degen, F. Boue, J.M. Livrozet, E. Van-steenberge, C.L. Yong1, J. Wu, F.J. Mensa, L. Waldhauser, J. Steffgen, F. Berger, J. Stern, P. Robinson, A.M. Quinson. 49th ICAAC, San Francisco, USA, 2009

48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION)  K. ARASTEH, D. WARD, A. PLETTENBERG, JM. LIVROZET, A. WINSTON, C. CORDES, E. WANG, A. QUINSON. 10th International Congress on Drug Therapy in HIV Infection, Glasgow, November 7-11, 2010

Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL, Robinson P, Quinson A. HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x. Epub 2011 Dec

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO. Gastroenterology. 2011 Dec;141(6):2047-55; quiz e14. Epub 2011 Sep 16.

4 week therapy with the non-nucleosidic polymerase inhibitor BI 207127 in combination with peginterferon-alfa2A and ribavirin in treatment naïve and treatment experienced chronic HCV GT1 patients. Dominique Larrey, Ansgar Lohse, Victor de Ledinghen, Christian Trepo, Tilman Gerlach, Jean-Pierre Zarski, Albert Tran, Philippe Mathurin, Robert Thimme, Keikawus Arastéh, Christian Trautwein,  Andreas Cerny, Nektarios Dikopoulos, Marcus Schuch- mann, Markus H. Heim, Guido Gerken, Jerry Stern, Katherine Wu, Nasri Abdallah, Birgit Girlich, Joseph Scherer, Wulf Boecher, Frank Berger, Jürgen Steffgen. Gastroenterology. 2011 Dec;141(6):2047-55; quiz e14. Epub 2011 Sep 16.

The SOUND-C1 study: High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127, and ribavirin, followed by BI201335 and PegIFN/ribavirin Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean Pierre Zarski, Dominique Larrey, Beat Müllhaupt, Ed Gane, Marcus Schuchmann, Ansgar Lohse, Stanislas Pol, Joseph Moussalli, Jean-P. Bronowicki, Stuart Roberts, Keikawus Arasteh, Fabien Zoulim, Jerry O. Stern, Federico Mensa, Gerhard Nehmiz, Carla Häfner, Wulf Otto Böcher. Poster, International Conference on Viral Hepatitis, March 26-27 2012

TRANxITION 144-week results: switching virologically stable HIV patients from immediate-release nevirapine (NVP IR) to extended-release NVP (XR) K Arastéh, M Drulak, J Guo, J Livrozet, C Orkin, A Quinson, D Ward. Journal of the International AIDS Society 2012, 15(Suppl 4):183

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K. HIV Med. 2012 Aug;13(7):406-15. doi: 10.1111/j.1468-1293.2012.00991.x. Epub 2012 Mar 14.

Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals. Cynthia Brinson, Sharon Walmsley, Keikawus Arasteh, Miguel Gorgolas, Lothar Schneider, Clare Brennan, Keith Pappa, Steve Almond, Catherine Granier, Francois Raffi. 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA

STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-coinfected patients treated with faldaprevir plus PegIFN and RBV Douglas Dieterich, Vicente Soriano,2 Mark Nelson, Jürgen Kurt Rockstroh, Keikawus Arastéh, Sanjay Bhagani,Andrew Talal, Cristina Tural, Richard Vinisko, and Jens Kort, 20th Conference on Retroviruses and Opportunistic Infections, March 3–6, 2013

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results Joel E. Gallant,  Ellen Koenig,  Jaime Andrade-Villanueva, Ploenchan Chetchotisakd6, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee and Andrew K. Cheng,  Journal of Infectious Diseases 208(1):32-39. July 1, 2013

STARTVerso 3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection Jacobson, Asselah, Ferenci, Foster, Jensen, Negro, Mantry, Wright, Forns, Garcia-Samaniego, Oliveira, Carvalho, Forton, Arastéh, Cooper, Ghesquiere, Dufour, Sakai, Tanaka, Stern, Sha, Boecher, Steinmann, Quinson, on behalf of the STARTVerso3 Study Group, American Association for the Study of the Liver: The Liver Meeting 2013. Poster Number 1100

STARTVerso 4 Phase III Trial of Faldaprevir Once-daily Plus Peg Interferon Alfa-2a and Ribavirin (PR) in Patients with HIV and HCV Genotype 1 Coinfection: End of Treatment Response (ETR) Jürgen Kurt Rockstroh, Mark Nelson, Vicente Soriano, Keikawus Arastéh, Josep Guardiola, Sanjay Bhagani, Josep Mallolas, Cristina Tural, Massimo Puoti, Patrick Ingiliz, Manuel Battega, Mamta K. Jain, Marina Nunez, Kristen Marks, Jens Kort, Jerry Stern, Richard Vinisko, Montserrat Manero, Douglas Dieterich, 14th European AIDS Conference (EACS), 16.-19. October 2013

TRANxITION 144 Week Results: Switching Virologically Stable HIV Patients From Immediate-Release Nevirapine (NVP IR) to Extended-Release NVP (XR) Keikawus Arasteh, Murray Drulak, Junhai Guo, Jean-Michel Livrozet, Chloe Orkin, Ann-Marie Quinson and Douglas Ward, J AIDS Clin Res 2014, 5:4

Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1–Infected Patients Stellbrink, Hans-Jürgen; Arastéh, Keikawus; Schürmann, Dirk; Stephan, Christoph; Dierynck, Inge; Smyej, Ilham; Hoetelmans, Richard M. W.; Truyers, Carla; Meyvisch, Paul ; Jacquemyn, Bert; Mariën, Kris; Simmen, Kenneth; Verloes, René;  JAIDS Journal of Acquired Immune Deficiency Syndromes:1 March 2014 – Volume 65 – Issue 3 – p 283–289

Faldaprevir Plus Pegylated Interferon α-2a/Ribavirin in HIV/HCV Co‑infection: STARTVerso4  Douglas Dieterich, Cristina Tural, Mark Nelson, Keikawus Arastéh, Vicente Soriano, Josep Guardiola, Sanjay Bhagani, Jürgen K Rockstroh, Jerry O Stern, Anne-Marie Quinson, The 2014 Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014

Effect of Faldaprevir on Atazanavir Pharmacokinetics in Patients with HIV/HCV Co-Infection Mark Nelson, Keikawus Arastéh, Mamta K Jain, Vicente Soriano, José Valdez Madruga, Juvencio Furtado, Manuel Battegay, Fenglei Huang, Montserrat Manero, Douglas Dieterich, The 2014 Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014

Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in ART-Naive HIV Infected Patients J. O. Morales-Ramirez, J. M. Gatell, D. P. Hagins, M. Thompson, K. Arasteh, C. Hoffmann, C. Harvey, X. Xu, H. Teppler, The 2014 Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014

SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAÏVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS Douglas Dieterich, Peter Ferenci, Ira M Jacobson, Francesco Negro, Massimo Puoti, Jürgen K Rockstroh, Michael P Manns, Keikawus Arastéh, Célia Oliveira, Jean-François Dufour, Elmar Zehnter, Clifford Leen, Sanjay Bhagani, Jerry O Stern, Anne-Marie Quinson, Joseph Scherer, Montserrat Manero, Donald M Jensen, 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9–13, 2014

Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study Thomas Harrer, Andreas Plettenberg, Keikawus Arastéh, Jan Van Lunzen, Gerd Fätkenheuer, Hans Jaeger, Michel Janssens Wivine Burny, Alix Collard, François Roman, Alfred Loeliger, Marguerite Koutsoukos, Patricia Bourguignon, Ludo Lavreys, Gerald Voss. Vaccine,Volume 32, Issue 22, 7 May 2014, Pages 2657-2665

Simplification to Stribild vs Continuation of RTV-boosted DRV with FTC and TDF in Virologically Suppressed HIV Adults: A STRATEGY-PI Subgroup Analysis J Arribas, G Rizzardini, K Arastéh, C Zurawski, C Dietz, D Pontani, W Garner, and T Nguyen P273 HIV Drug Therapy, Nov 2-6 2014, Glasgow

Simplification to the STRIBILD single tablet regimen from PI plus RTV plus FTC/TDF multi-pill regimens maintains durable HIV suppression: Week 96 results of STRATEGY-PI (Study 115) K. Arastéh, H.J. Stellbrink, J.K. Rockstroh, A. Rieger, J. Arribas, E. DeJesus, C. Zurawski, M. Doroana, W. Towner, A. Lazzarin, M. Nelson, C. Müller, D. McColl, R. Swamy, T. Nguyen DÖAK 2015 24-27. Juni 2015, Düsseldorf, Germany

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized Trials. Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J Jr, Walmsley S. AIDS. 2015 Jan 14;29(2):167-74.

Efficacy and Safety of Doravirine 100mg qd with TDF/FTC after 24 Weeks of Treatment in ART-Naive HIV-Infected Patients Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla Sogorb, Christian Hoffmann, Keikawus Arasteh, Melanie Thompson, Debbie P. Hagins, Javier O. Morales-Ramirez, Xia Xu, Hedy Teppler.  AIDS 2015, Vancouver BC

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection Stefan Bourgeois*, Hans Van Vlierberghe, Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M Schattenberg, Peter Buggisch, Sven Francque, Leen Vijgen, Thomas N Kakuda, Eva Hoeben, Donghan Luo, An Vandebosch, Bert Jacquemyn, Pieter Van Remoorter, Rene Verloes. Antiviral Therapy 2016

Doravirine 100 mg QD vs Efavirenz +TDF/FTC in ART- Naive HIV+ Patients: Week 48 Results. Jose M. Gatell; Francois Raffi; Andreas Plettenberg; Don Smith; Joaquin Portilla; Christian Hoffmann; Keikawus Arastéh; Melanie Thompson; Xia Xu; Hedy Teppler for the 1439-007 Study Team. Abstract #470 • CROI 2016, Boston MA, USA